Interim PET-directed therapy in limited-stage Hodgkin lymphoma initially treated with ABVD.
作者信息
Villa Diego, Sehn Laurie H, Aquino-Parsons Christina, Tonseth Petter, Scott David W, Gerrie Alina S, Wilson Donald, Bénard François, Gascoyne Randy D, Slack Graham W, Farinha Pedro, Morris James, Pickles Tom, Connors Joseph M, Savage Kerry J
机构信息
BC Cancer Centre for Lymphoid Cancer and Division of Medical Oncology
BC Cancer Centre for Lymphoid Cancer and Division of Medical Oncology.
出版信息
Haematologica. 2018 Dec;103(12):e590-e593. doi: 10.3324/haematol.2018.196782. Epub 2018 Jul 12.
Abstract
摘要
相似文献
1
Interim PET-directed therapy in limited-stage Hodgkin lymphoma initially treated with ABVD.初始采用ABVD方案治疗的局限期霍奇金淋巴瘤的中期PET指导下的治疗
Haematologica. 2018 Dec;103(12):e590-e593. doi: 10.3324/haematol.2018.196782. Epub 2018 Jul 12.
2
Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy.早期霍奇金淋巴瘤 ABVD 两个周期后的中期 PET：继续化疗加放疗后的结果。
Int J Radiat Oncol Biol Phys. 2015 Aug 1;92(5):1077-1083. doi: 10.1016/j.ijrobp.2015.04.021. Epub 2015 Apr 17.
3
2-deoxy-2[F-18] fluoro-D-glucose positron emission tomography Deauville scale and core-needle biopsy to determine successful management after six doxorubicin, bleomycin, vinblastine and dacarbazine cycles in advanced-stage Hodgkin lymphoma.2-脱氧-2[F-18]氟代-D-葡萄糖正电子发射断层扫描 Deauville 评分与核心针活检在晚期霍奇金淋巴瘤中六周期多柔比星、博来霉素、长春花碱和达卡巴嗪治疗后的成功管理中的作用
Eur J Cancer. 2020 Jun;132:85-97. doi: 10.1016/j.ejca.2020.03.008. Epub 2020 Apr 23.
4
Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients.基于中期PET/CT对早期和晚期霍奇金淋巴瘤初始治疗进行调整是有益的：一项针对355例患者的前瞻性多中心试验。
Br J Haematol. 2017 Sep;178(5):709-718. doi: 10.1111/bjh.14734. Epub 2017 Jun 7.
5
Very low utility of surveillance imaging in early-stage classic Hodgkin lymphoma treated with a combination of doxorubicin, bleomycin, vinblastine, and dacarbazine and radiation therapy.在接受多柔比星、博来霉素、长春花碱和达卡巴嗪联合化疗及放射治疗的早期经典型霍奇金淋巴瘤中，监测成像的效用非常低。
Cancer. 2015 Jun 15;121(12):1985-92. doi: 10.1002/cncr.29277. Epub 2015 Mar 4.
6
Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group.正电子发射断层扫描指导早期有利型霍奇金淋巴瘤治疗：德国霍奇金研究组国际、随机 III 期 HD16 试验的最终结果。
J Clin Oncol. 2019 Nov 1;37(31):2835-2845. doi: 10.1200/JCO.19.00964. Epub 2019 Sep 10.
7
The Utility of PET/CT in Guiding Radiotherapy Reduction for Children With Hodgkin Lymphoma Treated With ABVD.PET/CT在指导接受ABVD方案治疗的儿童霍奇金淋巴瘤放疗减量中的应用
J Pediatr Hematol Oncol. 2020 Mar;42(2):e87-e93. doi: 10.1097/MPH.0000000000001534.
8
Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial.在正电子发射断层扫描时代之前，反应引导的ABVD化疗联合受累野放射治疗用于中期霍奇金淋巴瘤：一项意大利淋巴瘤研究组（GISL）的前瞻性试验。
Clin Lymphoma Myeloma. 2009 Apr;9(2):138-44. doi: 10.3816/CLM.2009.n.034.
9
Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial.早期正电子发射断层扫描阴性 I/II 期霍奇金淋巴瘤中省略放疗与早期复发风险增加相关：前瞻性随机 EORTC/LYSA/FIL H10 试验的中期分析的临床结果。
J Clin Oncol. 2014 Apr 20;32(12):1188-94. doi: 10.1200/JCO.2013.51.9298. Epub 2014 Mar 17.
10
Risk-adapted therapy with three or six cycles of doxorubicin/bleomycin/vinblastine/dacarbazine plus involved-field radiation therapy in Hodgkin lymphoma, based on prognosis at diagnosis and early response: results from the GATLA study.基于诊断时预后和早期反应的情况，采用多柔比星/博来霉素/长春花碱/达卡巴嗪联合受累野放疗进行三或六周期风险适应性治疗霍奇金淋巴瘤：GATLA 研究结果。
Clin Lymphoma Myeloma Leuk. 2010 Jun;10(3):181-5. doi: 10.3816/CLML.2010.n.028.
引用本文的文献
1
Management of limited-stage Hodgkin lymphoma.局限性 Hodgkin 淋巴瘤的治疗管理。
Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):500-509. doi: 10.1182/hematology.2023000511.
2
Application of interim PET-CT in first-line treatment decision-making for lymphoma.中期PET-CT在淋巴瘤一线治疗决策中的应用。
J Zhejiang Univ Sci B. 2023 Oct 15;24(10):905-921. doi: 10.1631/jzus.B2200644.
3
Pegfilgrastim in Supportive Care of Hodgkin Lymphoma.培非格司亭在霍奇金淋巴瘤支持性治疗中的应用
Cancers (Basel). 2022 Aug 23;14(17):4063. doi: 10.3390/cancers14174063.
4
The outcome of older adults with classic Hodgkin lymphoma in British Columbia.不列颠哥伦比亚省老年经典霍奇金淋巴瘤患者的结局。
Blood Adv. 2022 Nov 22;6(22):5924-5932. doi: 10.1182/bloodadvances.2022008258.
5
Outcome of limited-stage nodular lymphocyte-predominant Hodgkin lymphoma and the impact of a PET-adapted approach.局限期结节性淋巴细胞为主型霍奇金淋巴瘤的预后及PET适应性治疗方法的影响。
Blood Adv. 2021 Sep 28;5(18):3647-3655. doi: 10.1182/bloodadvances.2021004375.
6
Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies.复发性/难治性霍奇金淋巴瘤的治疗效果优化：当前及未来治疗策略综述
Ther Adv Hematol. 2020 Feb 16;11:2040620720902911. doi: 10.1177/2040620720902911. eCollection 2020.
7
Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies.成人霍奇金淋巴瘤预后的中期PET结果：预后因素研究的系统评价和荟萃分析
Cochrane Database Syst Rev. 2020 Jan 13;1(1):CD012643. doi: 10.1002/14651858.CD012643.pub3.
8
Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies.成人霍奇金淋巴瘤预后的中期PET结果：一项预后因素研究的系统评价和荟萃分析
Cochrane Database Syst Rev. 2019 Sep 16;9(9):CD012643. doi: 10.1002/14651858.CD012643.pub2.
本文引用的文献
1
CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET.CALGB 50604：基于中期 PET 的非大肿块早期霍奇金淋巴瘤风险适应性治疗。
Blood. 2018 Sep 6;132(10):1013-1021. doi: 10.1182/blood-2018-01-827246. Epub 2018 Jul 26.
2
Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials.早期霍奇金淋巴瘤当代治疗的长期随访：德国霍奇金研究组 HD7、HD8、HD10 和 HD11 试验的更新分析。
J Clin Oncol. 2017 Jun 20;35(18):1999-2007. doi: 10.1200/JCO.2016.70.9410. Epub 2017 Apr 18.
3
Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial.早期正电子发射断层扫描反应适应性治疗 I 期和 II 期霍奇金淋巴瘤：随机 EORTC/LYSA/FIL H10 试验的最终结果。
J Clin Oncol. 2017 Jun 1;35(16):1786-1794. doi: 10.1200/JCO.2016.68.6394. Epub 2017 Mar 14.
4
Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma.霍奇金淋巴瘤治疗后 40 年内的二次癌症风险。
N Engl J Med. 2015 Dec 24;373(26):2499-511. doi: 10.1056/NEJMoa1505949.
5
Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma.早期霍奇金淋巴瘤的 PET 导向治疗试验结果。
N Engl J Med. 2015 Apr 23;372(17):1598-607. doi: 10.1056/NEJMoa1408648.
6
Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.影像学在淋巴瘤分期及疗效评估中的作用：恶性淋巴瘤国际会议影像工作组共识
J Clin Oncol. 2014 Sep 20;32(27):3048-58. doi: 10.1200/JCO.2013.53.5229.
7
ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma.ABVD 方案单用与放疗在局限期霍奇金淋巴瘤中的比较。
N Engl J Med. 2012 Feb 2;366(5):399-408. doi: 10.1056/NEJMoa1111961. Epub 2011 Dec 11.
8
Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8-9 April 2010.2010 年 4 月 8 日至 9 日在法国芒通举行的第二届淋巴瘤中期正电子发射断层扫描国际研讨会报告。
Leuk Lymphoma. 2010 Dec;51(12):2171-80. doi: 10.3109/10428194.2010.529208. Epub 2010 Nov 15.
9
Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size.受累淋巴结放射治疗作为局限期霍奇金淋巴瘤联合治疗的一部分：照射野大小的问题。
J Clin Oncol. 2008 Nov 10;26(32):5170-4. doi: 10.1200/JCO.2007.15.1001. Epub 2008 Oct 6.
10
Revised response criteria for malignant lymphoma.恶性淋巴瘤修订后的反应标准。
J Clin Oncol. 2007 Feb 10;25(5):579-86. doi: 10.1200/JCO.2006.09.2403. Epub 2007 Jan 22.
Zotero 插件